Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Non-lupus full-house nephropathy (NLFHN) is characterized by lupus-like immune complex deposition in the kidneys without systemic lupus erythematosus (SLE). Recent systematic analyses (Clin J Am Soc Nephrol 2024; 19: 743–754) hae identified NLFHN as a distinct clinicopathologic entity, often exhibiting "near full-house" patterns lacking IgA and with weak IgM. Evidence for the use of voclosporin in SLE-negative kidney-limited disease is limited, and management can be challenging when pregnancy is planned because of the teratogenicity of mycophenolate mofetil (MMF). This case illustrates that voclosporin is a safer alternative for pregnancy-oriented immunosuppression.
A 37-year-old woman presented with nephrotic-range proteinuria during routine screening. Urinalysis showed protein 7.17 g/gCr, positive occult blood, and 10–19 RBCs/HPF, with normal renal function. The results for autoantibodies, cryoglobulins, and hepatitis B/C antigens were negative. Complement C3/C4 levels were normal, with CH50 mildly decreased. A kidney biopsy (day 0) revealed diffuse endocapillary hypercellularity and subepithelial deposits resembling class IV/V lupus nephritis. Immunofluorescence demonstrated strong IgG, C3, and C1q; weak IgM; and negative IgA, consistent with a "near full-house" pattern. Methylprednisolone (500 mg/day × 3 days; days 64–66) was followed by oral prednisolone (25 mg/day from day 67) plus MMF 1000 mg/day, escalated to 1500 mg/day on day 86. Proteinuria declined rapidly, achieving complete remission by day 70 (UPCR < 0.5 g/gCr). The PSL dosage was tapered to 20 mg (day 121), 15 mg (day 149), 12.5 mg (day 177), 10 mg (day 212), 5 mg (day 261), and 2.5 mg (day 365). voclosporin (7.9 mg twice daily) was introduced on day 247 to facilitate pregnancy planning, followed by gradual MMF dose reduction aiming for complete withdrawal, while voclosporin maintained remission as a bridge therapy.
After voclosporin initiation, proteinuria remained suppressed, and complete remission persisted for > 12 months. Renal function and complement levels remained stable, without autoantibody seroconversion. Cryoglobulin negativity and the absence of secondary causes supported idiopathic, kidney-limited NLFHN. No treatment-related hypertension, neurotoxicity, or infection occurred. Serial follow-up confirmed sustained UPCR reduction and stable eGFR, demonstrating the long-term safety of voclosporin during MMF tapering. These observations support recent reports that "near full-house" patterns represent a distinct lupus-like glomerulopathy with non-systemic behavior under targeted immunosuppression.
This SLE-negative case (IgA–, IgM±) achieved early and sustained complete remission (day 70, UPCR < 0.5 g/gCr) through a pregnancy-conscious sequential regimen. voclosporin enabled progressive MMF reduction and safe transition toward preconception while preserving renal stability with low-dose steroids. These findings align with the recent systematic review that defines NLFHN as a distinct entity (Clin J Am Soc Nephrol 2024; 19: 743–754), highlighting voclosporin as a pregnancy-compatible, durable immunosuppressive option for rare glomerular diseases.
